Phase II Study of TAS-106 to Treat Head and Neck Cancer

Phase II Study of TAS-106 in Patients With Recurrent or Metastatic Head and Neck Cancer Refractory to Platinum Based Chemotherapy

The purpose of this study is to determine whether TAS-106 is effective to patients with recurrent or metastatic head and neck cancer refractory to platinum based chemotherapy.

Inclusion Criteria:

• Age 18 ≤ years old at study entry
• Histologically confirmed head and neck carcinoma
• Received prior platinum based regimen and developed disease progression or recurrence
• Measurable disease according to RECIST guidelines

Exclusion Criteria:

• Radiological or clinical evidence of brain involvement or leptomeningeal disease
• ≥ grade 2 peripheral neuropathy
• History of another malignancy